Go to the content. | Move to the navigation | Go to the site search | Go to the menu | Contacts | Accessibility

| Create Account

Pesce, Paola (2018) Non Alcoholic Fatty Liver Disease: non invasive markers of severity and new experimental treatments. [Ph.D. thesis]

Full text disponibile come:

PDF Document

Abstract (italian or english)

Non Alcoholic Fatty Liver Disease (NAFLD) is a worldwide increasing disease but still many questions about its evolution, the need of a screening and the availability of effective specific treatments are open.
Aims of this PhD project were:
1) the evaluation of NAFLD natural history in a subgroup of NAFLD affected diabetic patients enrolled during the daily clinical activity of a splenohepatology ecoDoppler laboratory in order to identify, if present, predictive factors of “evolutive NAFLD”;
2) the experimental evaluation, in High Fat Diet (HFD) fed rats, of the potential therapeutic effect of 3 molecules
targeting respectively:
a) lipid metabolism (Apolipoprotein A analogue compound -L4F),
b) insulin sensitivity (peroxisome proliferator activated receptor delta agonist –PPARd agonist)
c) endothelial function (EET Analog).
We developed two studies: a clinical observational study and an experimental study.
Clinical study:
100 patients with type 2 diabetes were evaluated as far as steatosis is concerned. Among them, 80 had sonographic signs of steatosis. There was no difference in the prevalence between male and female patients. 21 type 2 diabetic patients with liver steatosis were reevaluated after 6 years without any specific treatment. Liver steatosis increases only in less than 1/3 of non-obese diabetic patients and demonstrates that in the majority of them sonographic degree of steatosis improves or recovers concurrently with biohumoral parameters. The presence of increased levels of serum AST and ferritin and lower pulsatility index of haepatic artery seems to be correlated to a worse prognosis and may be used to identify those patients who deserve a higher surveillance.
Experimental study:
30 male Wistar rats (4-5 weeks old, 150 grams body weight) were purchased from Charles River Laboratories. 24 rats have been fed with HFD for 8 weeks. After 8 weeks of diet animals have been divided in 4 groups: 7 untreated (HFD); 7 treated with L4F (L4F), 7 treated with PPARd agonist (PPARd) and 3 treated with EET Analog (EET). Treatments lasted 6 weeks. We demonstrate that HFD induced NAFLD reproduces splanchnic haemodynamic alteration of liver steatosis in humans and shows an activation of innate immune system also at early degree of steatosis without hepatic inflammation and fibrosis. The activation of innate immune system can be evaluated by the analysis of lipopolysaccharide (LPS) stimulated/unstimulated CC motif chemockine ligand 2 (CCL2) production in cultured peripheral blood mononuclear cells (PBMCs).
PPARd agonist and L4F improved HFD induced liver steatosis and reduced CCL2 production in PBMCs but preserved the ability of PBMCs to react to LPS stimulation EETA administration didn’t improved liver steatosis and further decreased portal vein velocity and reduced the ability of PBMCs to react to LPS stimulation.

Statistiche Download
EPrint type:Ph.D. thesis
Tutor:Sacerdoti, David
Data di deposito della tesi:06 September 2019
Anno di Pubblicazione:07 November 2018
Key Words:Non alcoholic fatty liver disease (NAFLD) High Fat Diet (HFD) Innate immune system PPARd agonist L4f epoxyeicosatrienoic acid EETA
Settori scientifico-disciplinari MIUR:Area 06 - Scienze mediche > MED/09 Medicina interna
Struttura di riferimento:Dipartimenti > Dipartimento di Medicina
Codice ID:12035
Depositato il:07 Nov 2019 15:04
Simple Metadata
Full Metadata
EndNote Format


I riferimenti della bibliografia possono essere cercati con Cerca la citazione di AIRE, copiando il titolo dell'articolo (o del libro) e la rivista (se presente) nei campi appositi di "Cerca la Citazione di AIRE".
Le url contenute in alcuni riferimenti sono raggiungibili cliccando sul link alla fine della citazione (Vai!) e tramite Google (Ricerca con Google). Il risultato dipende dalla formattazione della citazione.

(1) Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J. Hepatol. 2015, 62, S65–S75. Cerca con Google

(2).Yatsuji S; Hashimoto E; Tobari M; Taniai M; Tokushige K; Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J. Gastroenterol. Hepatol. 2009, 24, 248–254. Cerca con Google

(3) Williams CD. et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140(1):124-131. Cerca con Google

(4) Armstrong M.J. et al. Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis. Diabetes Obes Metab 2014;16(7):651-660. Cerca con Google

(5) Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011,332:1519e1523. Cerca con Google

(6) Weiß J. et al. Non-Alcoholic Fatty Liver DiseaseEpidemiology, Clinical Course, Investigation, and Treatment. Review Article. Dtsch Arztebl Int. 2014 Jun; 111(26): 447–452. Cerca con Google

(7) Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe. A Review of available epidemiological data. European Association for the Study of the Liver 2013. J Hepatol. 2013;58:593–608. Cerca con Google

(8) Lee JY, Kim KM, Lee SG et al. Prevalence and risk factors of non alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol. 2007;47:239–244. Cerca con Google

(9) Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non alcoholic fatty liver disease and non alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–285. Cerca con Google

(10) Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors in non alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Liver Int. 2009;29:113–119. Cerca con Google

(11) Gaiani S, Avogaro A, Bombonato GC, Bolognesi M, Amor F, Vigili de Kreutzenberg S, Guarneri G, Sacerdoti D. Nonalcoholic fatty liver disease (NAFLD) in nonobese patients with diabetes: Prevalence and relationships with hemodynamic alterations detected with Doppler sonography. J Ultrasound. 2009 Mar;12(1):1-5. Cerca con Google

(12) Angulo P. Non alcoholic fatty liver disease. N Engl J Med. 2002;346:2121–1231. Cerca con Google

(13) Targher L, et al Relationship between Kidney Function and Liver Histology in Subjects with Nonalcoholic Steatohepatitis. Clin J Am Soc Nephrol. 2010 Dec; 5(12): 2166–2171. Cerca con Google

(14) Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005-23. Cerca con Google

(15) Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of nonalcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43(8):617-49. Cerca con Google

(16) Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53(6):1874-82. Cerca con Google

(17) Bahrami H, Daryani NE, Mirmomen S, Kamangar F, Haghpanah B, Djalili M. Clinical and histological features of nonalcoholic steatohepatitis in Iranian patients. BMC Gastroenterology. 2003; 3:27. Cerca con Google

(18) Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017 Jan;37 Suppl 1:81-84. Cerca con Google

(19) Pan MH, Lai CS, Tsai ML, Ho CT. Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds. Mol Nutr Food Res. 2014 Jan;58(1):147-71. Cerca con Google

(20) Machado VM, Cortez-Pinto H. Non-alcoholic fatty liver disease: What the clinician needs to know World J Gastroenterol. 2014 Sep 28; 20(36): 12956–12980. Cerca con Google

(21) Benedict M, Xuchen Zhang. Non-alcoholic fatty liver disease: An expanded review World J Hepatol. 2017 Jun 8; 9(16): 715–732. Cerca con Google

(22) Bertot LC, Adams LA.The Natural Course of Non-Alcoholic Fatty Liver Disease Int J Mol Sci. 2016 May; 17(5): 774. Cerca con Google

(23) Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–121. Cerca con Google

(24) Brunt EM, Kleiner DE, Wilson LA, Belt P and Neuschwander-Tetri BA, for the NASH CRN Hepatology. NAS and The Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings. Hepatology. 2011 Mar; 53(3): 810–820. Cerca con Google

(25) Fromenty B, Berson A, Pessayre D. Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation. J Hepatol. 1997;26(Suppl 1):13–22. Cerca con Google

(26). Fromenty B, Pessayre D. Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. J Hepatol. 1997;26(Suppl 2):43–53. Cerca con Google

(27) Tandra S et al. Presence and Significance of Microvesicular Steatosis in Nonalcoholic Fatty Liver Disease. J Hepatol. 2012 Sep 1. Author manuscript; available in PMC Cerca con Google

(28) Dowman JK, Tomlinson JW, Newsome PNQJM. Pathogenesis of non-alcoholic fatty liver disease. 2010 Feb;103(2):71-83. Cerca con Google

(29) Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343–51. Cerca con Google

(30) Day CP; James OF. Steatohepatitis: A tale of two “hits”? Gastroenterology 1998, 114, 842–845. Cerca con Google

(31) Betrapally NS, Gillevet PM, Bajaj JS. Changes in the Intestinal Microbiome and Alcoholic- and Nonalcoholic Liver Diseases—Causes or Effects? Gastroenterology. 2016 Jun; 150(8): 1745–1755.e3. Cerca con Google

(32). Francque S, Wamutu S, Chatterjee S, Van Marck E, Herman A, Ramon A, et al. Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulation in vitro and in vivo in a rat model. Liver international: official journal of the International Association for the Study of the Liver. 2010; 30(3):365–75. Cerca con Google

(33) Verreck FA, de Boer T, Langenberg DM, Hoeve MA, Kramer M, Vaisberg E, et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco) bacteria. Proceedings of the National Academy of Sciences of the United States of America. 2004; 1101 (13):4560–5. Cerca con Google

(34) Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nature medicine. 2009; 15(8):930–9. Cerca con Google

(35) Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Annals of internal medicine. 2002; 137(1):1–10. Cerca con Google

(36) Lebrec D, Goldfarb G, Degott C, Rueff B, Benhamou JP. Transvenous liver biopsy: an experience based on 1000 hepatic tissue samplings with this procedure. Gastroenterology. 1982; 83(2):338–40. Cerca con Google

(37) Bosch J, Garcia-Pagan JC, Berzigotti A, Abraldes JG. Measurement of portal pressure and its role in the management of chronic liver disease. Seminars in liver disease. 2006; 26(4):348–62. Cerca con Google

(38) Kalambokis G, Manousou P, Vibhakorn S, Marelli L, Cholongitas E, Senzolo M, et al. Transjugular liver biopsy—indications, adequacy, quality of specimens, and complications—a systematic review. Journal of hepatology. 2007; 47(2):284–94 Cerca con Google

(39) Groszmann R, Vorobioff JD, Gao H. Measurement of portal pressure: when, how, and why to do it. Clinics in liver disease. 2006; 10(3):499–512. Cerca con Google

(40) Grasso P; Gangolli S; Gaunt I. Essentials of Pathology for Toxicologists. (2002) CRC Press. Retrieved 30 August 2011. Cerca con Google

(41) Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walters P. Molecular Biology of the Cell; Fourth Edition. (2002) New York and London: Garland Science. Cerca con Google

(42) Janeway, Charles; Paul Travers; Mark Walport; Mark Shlomchik Immunobiology; Fifth Edition. (2001).New York and London: Garland Science. Cerca con Google

(43) Stvrtinová, Viera; Ján Jakubovský; Ivan Hulín Inflammation and Fever from Pathophysiology: Principles of Disease. (1995). Cerca con Google

(44) Lotze MT; Trace, KJ High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nature Reviews. Immunology. 2005. 5 (4): 331–42. Cerca con Google

(45) Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006, 444, 860–867. Cerca con Google

(46) Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments. Nutrients. 2017 Apr; 9(4): 387. Cerca con Google

(47) Odegaard JI, Ricardo-Gonzalez RR; Eagle AR; Vats D, Morel CR et al. Alternative M2 activation of Kupffer cells by ppardelta ameliorates obesity-induced insulin resistance. Cell Metab. 2008, 7, 496–507. Cerca con Google

(48) Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis 2015, 239, 192–202. Cerca con Google

(49) Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: Time for reassessment. F1000 Prime Rep. 2014, 6, 13. Cerca con Google

(50) Sica A, Mantovani A. Macrophage plasticity and polarization: In vivo veritas. J. Clin. Investig. 2012, 122, 787–795. Cerca con Google

(51) Gordon, S.; Martinez, F.O. Alternative activation of macrophages: Mechanism and functions. Immunity 2010, 32, 593–604. Cerca con Google

(52) Matsuzawa N; Takamura T, Kurita S, Misu H; Ota T; Ando H; Yokoyama M; Honda M; Zen Y, Nakanuma Y et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 2007, 46, 1392–1403. Cerca con Google

(53) Sica A, Invernizzi P, Mantovani A. Macrophage plasticity and polarization in liver homeostasis and pathology. Hepatology 2014, 59, 2034–2042. Cerca con Google

(54) Wan J, Benkdane M, Teixeira-Clerc F, Bonnafous S, Louvet A; Lafdil F, Pecker F, Tran A, Gual P, Mallat A et al. M2 Kupffer cells promote M1 Kupffer cell apoptosis: A protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology 2014, 59, 130–142. Cerca con Google

(55) Louvet A, Teixeira-Clerc F, Chobert MN, Deveaux V, Pavoine C, Zimmer A, Pecker F, Mallat A, Lotersztajn S. Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology 2011, 54, 1217–1226. Cerca con Google

(56) Klein I, Cornejo JC, Polakos NK, John B, Wuensch SA, Topham DJ, Pierce RH, Crispe IN. Kupffer cell heterogeneity: Functional properties of bone marrow derived and sessile hepatic Cerca con Google

macrophages.Blood 2007, 110, 4077–4085. Cerca con Google

(57) Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K, Abouda G. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016, 387, 679–690. Cerca con Google

(58) Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 142: 711–725e716, 2012. Cerca con Google

(59) Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk, R. et al. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol. Rev. 2014, 66, 71–79. Cerca con Google

(60) Xu A, Wang Y, Keshaw H, Xu L.Y, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Investig. 2003, 112, 91–100. Cerca con Google

(61) Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Investig. 2003, 112, 1796–1808. Cerca con Google

(62) Obstfeld AE, Sugaru E, Thearle M, Francisco AM, Gayet C, Ginsberg, H.N.; Ables, E.V.; Ferrante, A.W., Jr. CC chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes 2010, 59, 916–925. Cerca con Google

(63) Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, Charo I, Leibel RL, Ferrante AWJr. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Investig. 2006, 116, 115–124. Cerca con Google

(64) Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Investig. 2006, 116, 1494–1505. Cerca con Google

(65) Lavine JE, Schwimmer JB, van Natta ML, Molleston JP, Murray KF, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The tonic randomized controlled trial. JAMA 2011, 305, 1659–1668. Cerca con Google

(66) Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, Kubota N, Ohtsuka-Kowatari N, et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J. Biol. Chem. 2006, 281, 26602–26614. Cerca con Google

(67) Mantovani A, Bonecchi R, Locati M. Tuning inflammation and immunity by chemokine sequestration: Decoys and more. Nat. Rev. Immunol. 2006, 6, 907–918. Cerca con Google

(68) Tamura Y, Sugimoto M, Murayama T, Ueda Y, Kanamori H, Ono K, et al. Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 2195–2201. Cerca con Google

(69) Inouye KE, Shi H, Howard JK, Daly CH, Lord GM, Rollins BJ, Flier JS. Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes 2007, 56, 2242–2250. Cerca con Google

(70) Kirk EA, Sagawa ZK, McDonald TO, O’Brien KD, Heinecke JW. Monocyte chemoattractant protein deficiency fails to restrain macrophage infiltration into adipose tissue. Diabetes 2008, 57, 1254–1261. Cerca con Google

(71) Haukeland JW, Damas JK, Konopski Z, Loberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjoro K, Aukrust P. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J. Hepatol. 2006, 44, 1167–1174. Cerca con Google

(72) Miura K, Yang L, van Rooijen N, Ohnishi H, Seki E. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 302, G1310–G1321. Cerca con Google

(73) Mariathasan S, Newton K, Monack D, Vucic D, French D, Lee W, Roose-Girma M, Erickson S, Dixit V. "Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf". Nature. 2004, 430 (6996): 213–8. Cerca con Google

(74) Martinon F, Burns K, Tschopp J. "The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta". Mol Cell. 2002, 10 (2): 417–26. Cerca con Google

(75) Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol. 2015; 12:387–400. Cerca con Google

(76) Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology. 2011;54:133–144. Cerca con Google

(77) Wree A, Eguchi A, McGeough MD, Pena CA, Johnson CD, Canbay A, et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology. 2014;59: 898–910. Cerca con Google

(78) Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482: 179–185. Cerca con Google

(79). Csak T, Pillai A, Ganz M, Lippai D, Petrasek J, Park JK, et al. Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis. Liver Int. 2014;34: 1402–1413. doi: 10.1111/liv.12537 [PMC free article][PubMed] Cerca con Google

(80) Teli MR, James OF, Burt AD, Bennett MK, Day CP: The natural history of non alcoholic fatty liver: a follow up study. Hepatology 1995; 22: 1714–9.]) Cerca con Google

(81) Grabowski GA, Du H, Charnas L. Lysosomal Acid Lipase Deficiencies: The Wolman Disease/Cholesteryl Ester Storage Disease Spectrum. In: The Online Metabolic and Molecular Bases of Inherited Diseases. Eds: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson KM, Mitchell G. Chapter 142 Available on line at: http://www.cuh.org.uk/addenbrookes/services/clinical/lysosomal/disorders/lysosomal_acid_lipase_deficiency.html. Vai! Cerca con Google

(82) Fasano T, Pisciotta L, Bocchi L, Guardamagna O, Assandro P, Rabacchi C, Zanoni P, Filocamo M, Bertolini S, Calandra S. Lysosomal lipase deficiency: Molecular characterization of eleven patients with wolman or cholesteryl ester storage disease. Mol. Genet. Metab. 2012;105:450–456. Cerca con Google

(83) Zschenker O, Illies T, Ameis D. Overexpression of lysosomal acid lipase and other proteins in atherosclerosis. J. Biochem. 2006;140:23–38. Cerca con Google

(84) Baratta F, Pastori D, del Ben M, Polimeni L, Labbadia G, di Santo S, Piemonte F, Tozzi G, Violi F, Angelico F. Reduced lysosomal acid lipase activity in adult patients with non-alcoholic fatty liver disease. EBioMedicine. 2015;2:750–754. Cerca con Google

(85) Baratta F, Pastori D, Polimeni L, Tozzi G, Violi F, Del Ben M, Leonardo A. Does Lysosomial Acid Lipase Reduction Play a Role in Adult Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2015 Dec; 16(12): 28014–28021. Cerca con Google

(86) Tovoli F, Napoli L, Negrini G, D'Addato S, Tozzi G, D'Amico J, Piscaglia F, Bolondi L. A Relative Deficiency of Lysosomal Acid Lypase Activity Characterizes Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2017 May 25;18(6). Cerca con Google

(87) Merriman RB, Ferrell LD, Patti MG, et al.: Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006; 44: 874–80. Cerca con Google

(88) Lavine JE, et al.: The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association. Hepatology 2012; 55: 2005–23. Cerca con Google

(89) Malek NP, Schmidt S, Huber P, Manns MP, Greten TF: The diagnosis and treatment of hepatocellular carcinoma. Dtsch Arztebl Int 2014; 111: 101–6. Cerca con Google

(90) Machado MV, Cortez-Pinto H: Non-invasive diagnosis of nonalcoholic fatty liver disease. A critical appraisal. J Hepatol 2013; 58: 1007–19. Cerca con Google

(91) Wiegand J, Berg T. The etiology, diagnosis and prevention of liver cirrhosis—part 1 of a series of liver cirrhosis. Dtsch Arztebl Int 2013; 110: 85–91. e15 Cerca con Google

(92) Gaia S, Carenzi S, Barilli AL, et al.: Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver d isease and chronic viral hepatitis. J Hepatol 2011; 54: 64–71. Cerca con Google

(93) Angulo P, Bugianesi E, Bjornsson ES, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 782–9. Cerca con Google

(94) Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356–62. Cerca con Google

(95) Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461–5. Cerca con Google

(96) Trépo E, Nahon P, Bontempi G, et al. Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data. H epatology 2013. Cerca con Google

(97) Mihmanli I, Kantarci F, Yilmaz MH, Gurses B, Selcuk D, Ogut G, et al. Effect of diffuse fatty infiltration of the liver on hepatic artery resistance index. J Clin Ultrasound. 2005;33:95–9. Cerca con Google

(98) Hizli S, Koçyigit A, Arslan N, Tuncel SA, Demircioglu F, Cakmakçi H, et al. Hepatic artery resistance in children with obesity and fatty liver. Indian J Pediatr. 2010;77:407–11. Cerca con Google

(99) Palmentieri B, de Sio I, La Mura V, Masarone M, Vecchione R, Bruno S, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis. 2006;38:485–9. Cerca con Google

(100) Mohammadi A, Ghasemi-rad M, Zahedi H, Toldi G, Alinia T. Effect of severity of steatosis as assessed ultrasonographically on hepatic vascular indices in non-alcoholic fatty liver disease. Med Ultrason. 2011;13:200–6. Cerca con Google

(101) Adams LA, Angulo P. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis. 2007;11:25–35. Cerca con Google

(102) Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of nonalcoholic steatohepatitis. Clin Liver Dis. 2007;11:37–54. Cerca con Google

(103) Kito Y, Nagino M, Nimura Y. Doppler sonography of hepatic arterial blood flow velocity after percutaneous transhepatic portal vein embolization. AJR Am J Roentgenol. 2001;176:909–12. Cerca con Google

(104) Erdogmus B, Tamer A, Buyukkaya R, Yazici B, Buyukkaya A, Korkut E, et al. Portal vein hemodynamics in patients with non-alcoholic fatty liver disease. Tohoku J Exp Med. 2008;215:89–93. Cerca con Google

(105) Balci A, Karazincir S, Sumbas H, Oter Y, Egilmez E, Inandi T. Effects of diffuse fatty infiltration of the liver on portal vein flow hemodynamics. J Clin Ultrasound. 2008;36:134–40. Cerca con Google

(106) Karasin M, Tokgoz O, Serifoglu I, Oz I, Erdem O. The doppler ultrasonographic evaluation of haemodynamic changes in hepatic vascular structures in patients with hepatosteatosis. Polish Journal of Radiology. 2014;79:299-304. Cerca con Google

(107) Topal NB Orcan S, Sıgırlı D, Orcan G, Eritmen Ü. Effects of fat accumulation in the liver on haemodynamic variables assessed by Doppler ultrasonography. J Clin Ultrasound. 2015;43(1):26-33. Cerca con Google

(108) Gonçalves Dos Reis Monteiro ML, Ferreira DE Almeida E Borges V, Machado DE, Alcântara T, Borges DE Araújo L, DE Fátima Pinheiro C, Lemos Debs Diniz AMinerva. Liver haemodynamic patterns in nonalcoholic steatosis: Doppler Ultrasonography and histological evaluation. Gastroenterol Dietol. 2016;62(1):19-29. Cerca con Google

(109) Oguzkurt L, Yildirim T, Torun D, Tercan F, Kizilkilic O, Niron EA. Hepatic vein Doppler waveform in patients with diffuse fatty infiltration of the liver. Eur J Radiol. 2005;54:253–7. Cerca con Google

(110) Mohammadinia AR, Bakhtavar K, Ebrahimi-Daryani N, Habibollahi P, Keramati MR, Fereshtehnejad SM, et al. Correlation of hepatic vein Doppler waveform and hepatic artery resistance index with the severity of nonalcoholic fatty liver disease. J Clin Ultrasound. 2010;38:346–52. Cerca con Google

(111) von Herbay A, Frieling T, Häussinger D. Association between duplex Doppler sonographic flow pattern in right hepatic vein and various liver diseases. J Clin Ultrasound. 2001;29:25–30. Cerca con Google

(112) Dietrich CF, Lee JH, Gottschalk R, Herrmann G, Sarrazin C, Caspary WF, et al. Hepatic and portal vein flow pattern in correlation with intrahepatic fat deposition and liver histology in patients with chronic hepatitis C. AJR Am J Roentgenol. 1998;171:437–43. Cerca con Google

(113) Pozniak MA. Clinical Doppler Ultrasound. New York, NY: Churchill Livingstone; 2000. Doppler ultrasound of the liver; pp. 141–84. Cerca con Google

(114) Padhmini Balasubramanian et al., Portal Venous and Hepatic Artery Hemodynamics in Patients with Non Alcoholic Fatty Liver Disease (NAFLD) Journal of Clinical and Diagnostic Research. 2016 Aug, Vol10(8): TC07-TC10 Cerca con Google

(115) Tarzamni MK, Khoshbaten M, Shohreh Sadrarhami S et al. Hepatic Artery and Portal Vein Doppler Indexes in Non-alcoholic Fatty Liver Disease Before and After Treatment to Prevent Unnecessary Health Care Costs. Int J Prev Med. 2014 Apr; 5(4): 472–477. Cerca con Google

(116) Pomrath K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR: Randomized controlled trial testing the effects of weight loss on nonalcolholic steatohepatitis. Hepatology 2010; 51: 121–9. Cerca con Google

(117) Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19: pp. 537-544. Cerca con Google

(118) Nair S, Diehl AM, Wiseman M, Farr GH and Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004; 20: pp. 23-28 Cerca con Google

(119) Hulin B, McCarthy PA, Gibbs EM. The glitazone family of antidiabetic agents. Current Pharmaceutical Design. 1996. 2: 85–102. Cerca con Google

(120) Waki H, Yamauchi T, Kadowaki T. Regulation of differentiation and hypertrophy of adipocytes and adipokine network by PPARgamma. Nihon Rinsho. 2010. 68 (2): 210–6. PMID 20158086. Cerca con Google

(121) Panigrahy D, Singer S, Shen, Lucy Q, Butterfield, Catherine E, Freedman, Deborah A, Chen, Emy J, Moses, Marsha A, Kilroy, et al. PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. Journal of Clinical Investigation. 2002. 110 (7): 923–32. Cerca con Google

(122) Sanyal AJ, Chalasani L, Kowdley KV, et al. Pioglitazone, vitamin E,or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362: 1675–85. Cerca con Google

(123) Haentjens P, Massaad D, Reynaert H, Peeters E, Van Meerhaeghe A, Vinken S, Poppe K and Velkeniers B. Identifying non-alcoholic fatty liver disease among asymptomatic overweight and obese individuals by clinical and biochemical characteristics. Acta Clin Belg 2009; 64: pp. 483-493 Cerca con Google

(124) Hasegawa T et al. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with nonalcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001; 15: pp. 1667-1672. Cerca con Google

(125) Sanyal AJ, Chalasani L, Kowdley KV, et al.: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362: 1675–85. Cerca con Google

(126) Dufour JF et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006; 4: pp. 1537-1543. Cerca con Google

(127) Sanyal AJ et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2: pp. 1107-1115 Cerca con Google

(128) Miller ER, Pastor-Barriuso R, Dalal D, Riemersmara, Appel LJ and Guallar E. Meta-analysis: highdosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: pp. 37-46. Cerca con Google

(129) Dietrich M, Jacques PF, Pencina MJ, Lanier K, Keyes MJ, Kaur G, Wolf PA, D'Agostino RB, and Vasan RS. Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: Does the underlying health status play a role? Atherosclerosis 2009; 205: pp. 549-553. Cerca con Google

(130) He XX, Wu XL, Chen RP, Chen C, Liu XG, Wu BJ, Huang ZM. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. PLoS One. 2016 Oct 6;11(10):e0162368. Cerca con Google

(131) Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced liver disease. Gastroenterology 2009; 137: pp. 532-540. Cerca con Google

(132) Mummadi RR, Kasturi KS, Chennareddygair S and Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clinical Gastro and Hepatol 2008; 6: pp. 1396-1402. Cerca con Google

(133) Chavez-Tapia NC, Tellez-Avila FI, Barrientose-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, and Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database of Systematic Reviews 2010. Cerca con Google

(134) Takahashi Y, Soejima Y, Fukusato T. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2012; 18(19): 2300-2308. Cerca con Google

(135) Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, Goldstein JL, Brown MS. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 1998; 12: 3182-3194. Cerca con Google

(136) Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 2006; 87: 1-16. Cerca con Google

(137) Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996; 84: 491-495. Cerca con Google

(138) Yao ZM, Vance DE. Reduction in VLDL, but not HDL, in plasma of rats deficient in choline. Biochem Cell Biol 1990; 68: 552-558. Cerca con Google

(139) Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000; 105: 1067-1075. Cerca con Google

(140) Chowdhry S, Nazmy MH, Meakin PJ, Dinkova-Kostova AT, Walsh SV, Tsujita T, Dillon JF, Ashford ML, Hayes JD. Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic Biol Med 2010; 48: 357-371. Cerca con Google

(141) Larter CZ, Yeh MM, Williams J, Bell-Anderson KS, Farrell GC. MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes. J Hepatol 2008; 49: 407-416. Cerca con Google

(142) Dela Peña A, Leclercq I, Field J, George J, Jones B, Farrell G. NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 2005; 129: 1663-1674. Cerca con Google

(143) Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 2004; 39: 1286-1296. Cerca con Google

(144) Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, Ponomarenko A, DeCarli LM. Model of nonalcoholic steatohepatitis. Am J Clin Nutr 2004; 79: 502-509. Cerca con Google

(145) Romestaing C, Piquet MA, Bedu E, Rouleau V, Dautresme M, Hourmand-Ollivier I, Filippi C, Duchamp C, Sibille B. Long term highly saturated fat diet does not induce NASH in Wistar rats. Nutr Metab (Lond) 2007; 4: 4 67. Cerca con Google

(146) Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, Yokoyama M, Honda M, Zen Y, Nakanuma Y, Miyamoto K, Kaneko S. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 2007; 46: 1392-1403. Cerca con Google

(147) Kawasaki T, Igarashi K, Koeda T, Sugimoto K, Nakagawa K, Hayashi S, Yamaji R, Inui H, Fukusato T, Yamanouchi T. Rats fed fructose-enriched diets have characteristics of nonalcoholic hepatic steatosis. J Nutr 2009; 139: 2067-2071. Cerca con Google

(148) Armutcu F, Coskun O, Gürel A, Kanter M, Can M, Ucar F, Unalacak M. Thymosin alpha 1 attenuates lipid peroxidation and improves fructose-induced steatohepatitis in rats. Clin Biochem 2005; 38: 540-547. Cerca con Google

(149) Vonghia L, Magrone T, Verrijken A, Michielsen P, Van Gaal L, Jirillo E, et al. (2015) Peripheral and Hepatic Vein Cytokine Levels in Correlation with Non-Alcoholic Fatty Liver Disease (NAFLD)-Related Metabolic, Histological, and Haemodynamic Features. PLoS ONE 10(11). Cerca con Google

(150) Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015 May;61(5):1547-54. Cerca con Google

(151) Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liverbiopsies at 3 years. Gut. 2010 Jul;59(7):969-74. Cerca con Google

(152) Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, Kechagias S.Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. Hepatol Commun. 2017 Nov 30;2(1):48-57. Cerca con Google

(153) Naga Chalasani, Zobair Younossi, Joel E. Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A. Harrison, Elizabeth M. Brunt and Arun J. Sanyal. The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases. PRACTICE GUIDANCE | HEPATOLOGY, VOL. 67, NO. 1, 2018. Cerca con Google

(154) Saverymuttu SH, Joseph AE, and MaxwellUltrasound scanning in the detection of hepatic fibrosis and steatosis. JD. Med J (Clin Res Ed). 1986 Jan 4; 292(6512): 13–15. Cerca con Google

(155) Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387–95. Cerca con Google

(156) Hashemi SJ, Hajiani E, Sardabi EH. A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver. Hepat Mon 2009;9:265–70. Cerca con Google

(157) Ioannou GN. Implications of elevated serum alanine aminotransferase levels: think outside the liver. Gastroenterology 2008;135:1851–4. Cerca con Google

(158) Jose Luis Martin-Rodriguez, Jorge Gonzalez-Cantero, Alvaro Gonzalez-Cantero, Juan Pedro Arrebola and Jorge Luis Gonzalez- Calvin. Diagnostic accuracy of serum alanine aminotransferase as biomarker for nonalcoholic fatty liver disease and insulin resistance in healthy subjects, using 3T MR spectroscopy Medicine (Baltimore). 2017 Apr; 96(17): e6770. Cerca con Google

(159) Ioannou GN. The Role of Cholesterol in the Pathogenesis of NASH. Trends Endocrinol Metab. 2016 Feb;27(2):84-95. Cerca con Google

(160) Gábor Firneisz. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: The liver disease of our age? World J Gastroenterol. 2014 Jul 21; 20(27): 9072–9089. Cerca con Google

(161) Tarantino G, Conca P, Riccio A, Tarantino M, di Minno MN, Chianese D, Pasanisi F, Contaldo F, Scopacasa F, Capone D. Enhanced serum concentrations of transforming growth factor-β1 in simple fatty liver: Is it really benign? J. Transl. Med. 2008;6:72. Cerca con Google

(162) Seyedian SS, Hajiani E, Hashemi SJ, Masjedizadeh A, Shayesteh AA, Alavinejad P, Hormati A, Javaherforoushzadeh A, Khabazkhoob M. Relationship between serum ferritin level and transient elastography findings among patients with nonalcoholic fatty liver disease. J Family Med Prim Care. 2017 Oct-Dec;6(4):750-754. Cerca con Google

(163) Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, Sanyal AJ, Nelson JE; NASH Clinical Research Network. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease Hepatology. 2012 Jan; 55(1):77-85. Cerca con Google

(164) Baik SK, Kim JW, Kim HS, Kwon SO, Kim YJ, Park JW, et al. Recent variceal bleeding: Doppler US hepatic vein waveform in assessment of severity of portal hypertension and vasoactive drug response. Radiology. 2006;240:574–80. Cerca con Google

(165) Gutierrez-Buey G, Núñez-Córdoba JM, Llavero-Valero M, Gargallo J, Salvador J, Escalada J. Is HOMA-IR a potential screening test for non-alcoholic fatty liver disease in adults with type 2 diabetes? Eur J Intern Med. 2017 Jun;41:74-78. Cerca con Google

(166) Abidullah Khan, Wazir Muhammad Khan, Maimoona Ayub, Mohammad Humayun, Mohammad Haroon. Ferritin Is a Marker of Inflammation rather than Iron Deficiency in Overweight and Obese People. J Obes. 2016; 2016: 1937320. Cerca con Google

(167) Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010; 52(5):1836 – 46. Cerca con Google

(168) Francque S, Wamutu S, Chatterjee S, Van Marck E, Herman A, Ramon A, et al. Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulation in vitro and in vivo in a rat model. Liver international: official journal of the International Association for the Study of the Liver. 2010; 30(3):365 – 75. Cerca con Google

(169) Karavia EA, Hatziri A, Kalogeropoulou C, Papachristou N, Xepapadaki E, Constantinou C, Natsos A, Petropoulou PI, Sasson S, Papachristou DJ, Kypreos KE. Deficiency in apolipoprotein A-I ablates the pharmacological effects of metformin on plasma glucose homeostasis and hepatic lipid deposition. Eur J Pharmacol. 2015 Nov 5;766:76-85. Cerca con Google

(170) Rao PK, Merath K, Drigalenko E, Jadhav AYL, Komorowski RA, Goldblatt MI, Rohatgi A, Sarzynski MA, Gawrieh S, Olivier M. Proteomic characterization of high-density lipoprotein particles in patients with non-alcoholic fatty liver disease. Clin Proteomics. 2018 Mar 6;15:10. Cerca con Google

(171) Navab M, Yu R, Gharavi N, Huang W, Ezra N, Lotfizadeh A, Anantharamaiah GM, Alipour N, Van Lenten BJ, Reddy ST, Marelli D. High-density lipoprotein: antioxidant and anti-inflammatory properties. Curr Atheroscler Rep. 2007 Sep;9(3):244-8. Review. Cerca con Google

(172) Sherman CB, Peterson SJ, Frishman WH. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. Cardiol Rev. 2010 May-Jun;18(3):141-7. Cerca con Google

(173) Wakabayashi K, Okamura M, Tsutsumi S, Nishikawa NS, Tanaka T, Sakakibara I, Kitakami J, Ihara S, Hashimoto Y, Hamakubo T, Kodama T, Aburatani H, Sakai J . The peroxisome proliferator- activated receptor gamma/retinoid X receptor alpha heterodimer targets the histone modification enzyme PR-Set7/Setd8 gene and regulates adipogenesis through a positive feedback loop. Mol Cell Biol. 2009 Jul;29(13):3544-55. Cerca con Google

(174) Zarei M, Barroso E, Palomer X1 Dai J, Rada P, Quesada- López T, Escolà-Gil JC, Cedó L, Zali MR, Molaei M, Dabiri R, Vázquez S, Pujol E, Valverde ÁM, Villarroya F, Liu Y, Wahli W, Vázquez-Carrera M. Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease. Mol Metab. 2018 Feb;8:117-131. Cerca con Google

(175) Hashimoto T, Cook WS, Qi C, Yeldandi AV, Reddy JK, Rao MS. Defect in peroxisome proliferatoractivated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem. 2000 Sep 15; 275(37):28918-28. Cerca con Google

(176) Magliano DC, Penna-de-Carvalho A, Vazquez-Carrera M, Mandarim-de-Lacerda CA, Aguila MB. Short-term administration of GW501516 improves inflammatory state in white adipose tissue and liver damage in high-fructose-fed mice through modulation of the renin-angiotensin system. Endocrine. 2015 Nov;50(2):355-67. Cerca con Google

(177) Spector AA. Arachidonic acid cytochrome P450 epoxygenase pathway. J Lipid Res. 2009 Apr;50 Suppl:S52-6. Cerca con Google

(178) Cheranov SY, Karpurapu M, Wang D, Zhang B, Venema RC, Rao GN.An essential role for SRCactivated STAT-3 in 14,15-EET-induced VEGF expression and angiogenesis. Blood. 2008 Jun 15;111(12):5581-91. Cerca con Google

(179) Sacerdoti D, Bolognesi M, Di PM, Gatta A, McGiff JC, Schwartzman ML, et al. Rat mesenteric arterial dilator response to 11,12-epoxyeicosatrienoic acid is mediated by activating heme oxygenase. Am J Physiol Heart Circ Physiol 2006;291:H1999-H2002 Cerca con Google

(180) Kaide J, Zhang F, Wei Y, Wang W, Gopal VR, Falck JR, et al. Vascular CO counterbalances the sensitizing influence of 20-HETE on agonist-induced vasoconstriction. Hypertension 2004;44:210-6. Cerca con Google

(181) Kaide J, Zhang F, Wei Y, Jiang H, Yu C, Wang WH, et al. Carbon monoxide of vascular origin attenuates the sensitivity of renal arterial vessels to vasoconstrictors. J Clin Invest 2001;107:1163-71. Cerca con Google

(182) Di Noia MA, Van DS, Palmieri F, Yang LM, Quan S, Goodman AI, et al. Heme oxygenase-1 enhances renal mitochondrial transport carriers and cytochrome C oxidase activity in experimental diabetes. J Biol Chem 2006;281:15687-93. Cerca con Google

(183) Goodman AI, Chander PN, Rezzani R, Schwartzman ML, Regan RF, Rodella L, et al. Heme oxygenase-2 deficiency contributes to diabetes-mediated increase in superoxide anion and renal dysfunction. J Am Soc Nephrol 2006;17:1073-81. Cerca con Google

(184) Sodhi K, Inoue K, Gotlinger KH, Canestraro M, Vanella L, Kim DH, et al. Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2 null mice. J Pharmacol Exp Ther 2009;331:906-16. Cerca con Google

(185) Elmarakby AA, Faulkner J, Baban B, Saleh MA, Sullivan JC. Induction of hemeoxygenase-1 reduces glomerular injury and apoptosis in diabetic spontaneously hypertensive rats. Am J Physiol Renal Physiol 2012;302:F791-F800 Cerca con Google

(186) Sacerdoti D, Pesce P, Di Pascoli M, Bolognesi M. EETs and HO-1 cross-talk. Prostaglandins Other Lipid Mediat. 2016 Sep;125:65-79. Cerca con Google

(187) Pierce AA, Duwaerts CC, Siao K, Mattis AN, Goodsell A, Baron JL, Maher JJ. CD18 deficiency improves liver injury in the MCD model of steatohepatitis. PLoS One. 2017 Sep 5;12(9):e0183912. Cerca con Google

(188) Mridha AR, Haczeyni F, Yeh MM, Haigh WG, Ioannou GN, Barn V, Ajamieh H, Adams L, Hamdorf JM, Teoh NC, Farrell GC. TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival. Clin Sci (Lond). 2017 Jul 24;131(16):2145-2159. Cerca con Google

(189) Stanley Ching-Cheng Huang, Bart Everts, Yulia Ivanova, David O'Sullivan, Marcia Nascimento, Amber M. Smith, Wandy Beatty et al. Cell-intrinsic lysosomal lipolysis is essential for macrophage alternative activation. Nat Immunol. 2014 Sep; 15(9): 846–855. Cerca con Google

(190) Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117:175–84. Cerca con Google

(191) Anderson EK, Hill AA, Hasty AH. Stearic acid accumulation in macrophages induces toll-like receptor 4/2-independent inflammation leading to endoplasmic reticulum stress-mediated apoptosis. Arterioscler Thromb Vasc Biol. 2012;32:1687–95. Cerca con Google

(192) Gui T, Shimokado A, Sun Y, Akasaka T, Muragaki Y. Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discovery. Mediat Inflamm. 2012; 2012:693083. Cerca con Google

(193) Leroux A, Ferrere G, Godie V, Cailleux F, Renoud ML, Gaudin F, et al. Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. J Hepatol. 2012;57:141–9. Cerca con Google

(194) Merla J. Hubler and Arion J. Kennedy. Role of lipids in the metabolism and activation of immune cells. J Nutr Biochem. 2016 Aug; 34: 1–7. Cerca con Google

(195) Toda K, Kumagai N, Tsuchimoto K, Inagaki H, Suzuki T, Oishi T, Atsukawa K, Saito H, Morizane T, Hibi T, Ishii H. Induction of hepatic stellate cell proliferation by LPS-stimulated peripheral blood mononuclear cells from patients with liver cirrhosis. J Gastroenterol. 2000;35(3):214-20. Cerca con Google

(196) Lee YH, Kim KJ, Yoo ME, Kim G, Yoon HJ, Jo K, Youn JC, Yun M, Park JY, Shim CY, Lee BW, Kang SM, Ha JW, Cha BS, Kang ES. Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients. J Hepatol. 2017 Nov 24. pii: S0168-8278(17)32448-0. Cerca con Google

(197) Mireille Ouimet, Vivian Franklin, Esther Mak, Xianghai Liao, Ira Tabas, Yves L. Marcel. Autophagy Regulates Cholesterol Efflux from Macrophage Foam Cells via Lysosomal Acid Lipase. Cell Metab. 2011 Jun 8; 13(6): 655–667. Cerca con Google

(198) Lee HJ, Yeon JE, Ko EJ, Yoon EL, Suh SJ, Kang K, Kim HR, Kang SH, Yoo YJ, Je J, Lee BJ, Kim JH, Seo YS, Yim HJ, Byun KS. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease. World J Gastroenterol. 2015 Dec 7;21(45):12787-99. Cerca con Google

(199) Seong Min Kim, Bonggi Lee, Hye Jin An, Dae Hyun Kim, Kyung Chul Park, Sang-Gyun Noh, Ki Wung Chung, Eun Kyeong Lee et al. Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging. Oncotarget. 2017 Jul 11; 8(28): 46273–46285. Published online 2017 May 8. Cerca con Google

(200) Dumortier J, Giostra E, Belbouab S, Morard I, Guillaud O, Spahr L, Boill ot O, Rubbia-Brandt L, Scoazec JY, Hadengue A. Non-alcoholic fatty liver disease in liver transplant recipients: another story of “seed and soil”. Am J Gastroenterol. 2010;105:613–620. Cerca con Google

(201) O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet. 2002;360:1119–1125. Cerca con Google

(202) Suman Kundu, Talat Roome, Ashish Bhattacharjee, Kevin A. Carnevale, Valentin P. Yakubenko, Renliang Zhang, Sung Hee Hwang, Bruce D. Hammock, Martha K. Metabolic products of soluble epoxide hydrolase are essential for monocyte chemotaxis to MCP-1 in vitro and in vivo. J Lipid Res. 2013 Feb; 54(2): 436–447. Cerca con Google

(203) Bolognesi M, Sacerdoti D, Di Pascoli M, Angeli P, Quarta S, Sticca A, Pontisso P, Merkel C, Gatta A. Haeme oxygenase mediates hyporeactivity to phenylephrine in the mesenteric vessels of cirrhotic rats with ascites Gut. 2005 Nov; 54(11): 1630–1636. Cerca con Google

(204) Pereira ENGDS, Silvares RR, Flores EEI, Rodrigues KL, Ramos IP, da Silva IJ, Machado MP, Miranda RA, Pazos-Moura CC, Gonçalves-de-Albuquerque CF, Faria-Neto HCC, Tibiriça E, Daliry A. Hepatic microvascular dysfunction and increased advanced glycation end products are components of nonalcoholic fatty liver disease. PLoS One. 2017 Jun 19;12(6):e0179654. Cerca con Google

(205) Vinolo MAR, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short chain fatty acids. Nutrients. 2011;3:858–876. Cerca con Google

(206) Flint HJ. Obesity and the gut microbiota. J Clin Gastroenterol. 2011;45:S128–S132. Cerca con Google

(207) Finelli C, Tarantino G. Is there any consensus as to what diet or lifestyle approach is the right one for NAFLD patients? J Gastrointest Liver Dis JGLD. 2012;21:293–302. Cerca con Google

Download statistics

Solo per lo Staff dell Archivio: Modifica questo record